Drug intelligence / Profile preview

SFT-401

Development stage: Unknown
Lead developer: Softhale
Modality: Inhalation Devices → Device-based Delivery → Drug Delivery Systems, Small Molecules
Administration: Inhalation

Overview

SFT-401 is an inhaled therapeutic candidate being developed by Softhale (a subsidiary of invoX Pharma) for the treatment of chronic obstructive pulmonary disease (COPD) and asthma. The drug is delivered using the proprietary Softhaler® inhalation platform, a propellant-free, soft mist inhaler (SMI) technology designed to optimize lung deposition and improve patient ease of use compared to traditional metered-dose or dry-powder inhalers. As of early 2024, SFT-401 is in Phase 1 clinical development. While the specific active pharmaceutical ingredient has not been publicly disclosed, the program is part of a specialized pipeline focused on high-efficiency delivery of respiratory medications.

Beyond the preview

Go deeper on SFT-401.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SFT-401.

Explore the full profile